Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

The WNT signaling pathway is a critical regulator of development and adult tissue
homeostasis and becomes dysregulated in many cancer types. Although hyperactivation of …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

Objective We previously reported a characterisation of the hepatocellular carcinoma (HCC)
immune contexture and described an immune-specific class. We now aim to further …

Organoid models have the potential to recapitulate the biological and pharmacotypic
features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis …

The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Hepatocellular carcinoma is the third leading cause of deaths from cancer worldwide.
Infection with the hepatitis B virus is one of the leading risk factors for developing …

We performed the first proteogenomic characterization of hepatitis B virus (HBV)-related
hepatocellular carcinoma (HCC) using paired tumor and adjacent liver tissues from 159 …

Hepatitis B virus (HBV) contributes to hepatocellular carcinoma (HCC) development through
direct and indirect mechanisms. HBV DNA integration into the host genome occurs at early …

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer-related death. Its
mortality has increased in Western populations, with a minority of patients diagnosed at …